AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05734144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The intraoperative ERCP has been performed immediately before LC
Description: combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
Study NCT05734144 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: POES followed by LC
Description: Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
Study NCT02850276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Study NCT03001726 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
Study NCT03001726 — intervention group
Intervention type: DRUG
Intervention: oxaliplatin
Description: oxaliplatin 100 mg/m2
Study NCT03001726 — intervention group
Intervention type: DRUG
Intervention: S1
Description: S1 40mg/m2
Study NCT01638585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urokinase
Description: daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
Study NCT03001726 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: docetaxel 40 mg/m2
Study NCT03636685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with pemetrexed and carboplatin, phase I
Description: Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin
Study NCT00753025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration, injection of cells
Description: Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle
Study NCT00753025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration , injection of isolated CD 133+ cells
Description: arm CD133 receives injection of isolated CD 133+ cells
Study NCT03636685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with paclitaxel and carboplatin, phase I
Description: Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin
Study NCT03636685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with pemetrexed and carboplatin, phase II
Description: Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
Study NCT03636685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with paclitaxel and carboplatin, phase II
Description: Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
Study NCT00753025 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow aspiration, injection of saline
Description: arm placebo receives injection of saline
Study NCT03841773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Study NCT03841773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablets
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Study NCT03062644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR308
Description: two times daily; Mode of Administration:oral
Study NCT03062644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: four times daily; Mode of Administration:oral
Study NCT03062644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: two times daily; Mode of Administration:oral
Study NCT03062644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MR308
Description: given four times daily to maintain the blind; Mode of Administration:oral
Study NCT03137524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Held Fan Therapy
Description: Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
Study NCT00820014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
Study NCT00820014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
Study NCT00362297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: 800 mg orally three times daily for 7 weeks
Study NCT00362297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: 500 mg orally once daily for 7 weeks
Study NCT01408862 — intervention group
Intervention type: OTHER
Intervention: venous puncture
Description: Blood for in vitro studies will be drawn
Study NCT01228084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
Study NCT01228084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT01228084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological study
Description: Correlative studies
Study NCT00806611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol Block
Description: Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
Study NCT00806611 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Block
Description: Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
Study NCT01078974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Taken orally once a day
Study NCT01078974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
Study NCT01078974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
Study NCT04228666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
Study NCT01804504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
Study NCT02181335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Respimat® Budesonide low dose
Study NCT02181335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Respimat® Budesonide high dose
Study NCT02181335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler® Budesonide
Study NCT01276366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breast feeding
Description: Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
Study NCT02181335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02681120 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Study NCT02604524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control
Description: Subjects will use the CLC during 5 nights/6 days at a ski camp.
Study NCT02604524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensor Augmented Pump Therapy
Description: Subjects using their personal pumps with study CGM.
Study NCT03893136 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
Study NCT03763474 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Euglyca application
Description: 'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
Study NCT00508131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Cows Milk
Description: 400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
Study NCT03893136 — intervention group
Intervention type: DRUG
Intervention: Leflunomide
Description: The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
Study NCT03034421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
Study NCT01394523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5%
Study NCT01276366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supplemental breast milk
Description: In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
Study NCT01276366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
Study NCT02988921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI and CT
Study NCT02988921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ratiotherapy
Study NCT00508131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole Cows Milk
Description: 400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
Study NCT05863169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fNIRS-Neurofeedback
Description: Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
Study NCT05863169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS-Neurofeedback
Description: Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
Study NCT03377738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry
Description: All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
Study NCT02805400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: determination of cortical activity
Description: Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used.
Study NCT04152434 — intervention group
Intervention type: DRUG
Intervention: Erenumab Auto-Injector
Description: Assess synergy of add on medication to Erenumab
Study NCT02181335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03639064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Oil
Description: Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil.
Study NCT04384991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: Cyclosporine 0.02% with Trehalose 3%
Study NCT04384991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis eye drop
Description: Cyclosporine 0.05%
Study NCT03606889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block
Description: 0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
Study NCT02031224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional low protein diet
Study NCT02031224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low protein diet supplemented with Ketosteril
Study NCT01030185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaShunt's Automated Fluid Shunt implantation
Description: The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
Study NCT02691403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levo-bupivacaine
Study NCT02691403 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Study NCT01561547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
Study NCT01561547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
Study NCT01561547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
Study NCT01333995 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peer counseling on infant feeding
Description: Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
Study NCT02443909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
Study NCT02443909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser device
Study NCT01724424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg oral single dose
Study NCT01724424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 30 mg oral single dose
Study NCT01004744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg PO daily for two weeks prior to scheduled surgery
Study NCT02988921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, platinum-based drug
Study NCT01073709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT01724424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 50mg oral single dose
Study NCT01724424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 100mg oral single dose
Study NCT01073709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 180 mcg/kg 3 days prior to chemotherapy
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose 3 days prior to chemotherapy
Study NCT02262104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
Study NCT02262104 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
Study NCT01706042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: legume meal
Study NCT01706042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: white bread
Study NCT00442091 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dandelion juice
Description: 10 ml bid for 20-30 days
Study NCT00393341 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood sample will be drawn from a vein in the arm.
Study NCT03790800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urapidil
Description: A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists >150 after 5 minutes.
Study NCT00086502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Sitagliptin
Description: Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
Study NCT03585920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Corn Snack
Description: A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
Study NCT03585920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expanded Corn Snack
Description: A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
Study NCT03364842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Administering furosemide
Study NCT02498028 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical Fusion
Description: Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)